CAS Registry Number is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
== Human pathogenicity == Species within the genus Penicillium do not generally cause disease in humans. However, being one of the most common producers of indoor moulds, certain species can become pathogenic upon long-term exposure, as well as for individuals who are immunocompromised or hyper-sensitized to certain parts of the fungus. Spores, proteolytic enzymes, and glycoproteins are amongst the components commonly reported as allergens in humans and animal models. Within this context, members of Penicillium have been associated with a variety of immunological manifestations such as Type 1 allergic responses, hypersensitivity pneumonitis (Type 3 responses), and immediate and delayed asthma. With respect to P. digitatum, this species is known to cause a generalized fungal infection (mycosis) in humans, although the incidence of such events is very low. Various studies have also noted a presence of circulating antibodies to the extracellular polysaccharide of P. digitatum, in both human and rabbit sera. This presence is suggested to be due to the intake of contaminated fruits and/or breathing air contaminated with extracellular polysaccharide. In terms of allergy testing, P. digitatum is present in various clinical allergy test formulations, testing for allergy to moulds. There has been one case report identifying P. digitatum as the cause of a fatal case of pneumonia, via molecular methods.
The Parliament of Jamaica is the legislative branch of the government of Jamaica. It is a bicameral body, composed of an appointed Senate and an elected House of Representatives. The Senate (upper house), the direct successor of a pre-Independence body known as the "Legislative Council"—comprises 21 senators appointed by the governor-general: thirteen on the advice of the prime minister and eight on the advice of the leader of the opposition. The House of Representatives, the lower house, is made up of 63 (previously 60) members of Parliament, elected to five-year terms on a first-past-the-post basis in single-seat constituencies.
The anatomy of arteries can be separated into gross anatomy, at the macroscopic level, and microanatomy, which must be studied with a microscope. The arterial system of the human body is divided into systemic arteries, carrying blood from the heart to the whole body, and pulmonary arteries, carrying deoxygenated blood from the heart to the lungs. Large arteries (such as the aorta) are composed of many different types of cells, namely endothelial, smooth muscle, fibroblast, and immune cells. As with veins, the arterial wall consists of three layers called tunics, namely the tunica intima, tunica media, and tunica externa, from innermost to outermost. The externa, alternatively known as the tunica adventitia, is composed of collagen fibers and elastic tissue—with the largest arteries containing vasa vasorum, small blood vessels that supply the walls of large blood vessels. Most of the layers have a clear boundary between them, however the tunica externa has a boundary that is ill-defined. Normally its boundary is considered when it meets or touches the connective tissue. Inside this layer is the tunica media, which is made up of smooth muscle cells, elastic tissue (also called connective tissue proper) and collagen fibres. The innermost layer, which is in direct contact with the flow of blood, is the tunica intima. The elastic tissue allows the artery to bend and fit through places in the body. This layer is mainly made up of endothelial cells (and a supporting layer of elastin rich collagen in elastic arteries).
Sources: en.wikipedia.org
Russula cyanoxantha – high quality edible with blue to greenish cap, mild taste and white, greasy gills. Russula emetica Russula subnigricans – a poisonous mushroom causing rhabdomyolysis in Japan, China, and Taiwan. Russula virescens – an excellent edible, recognizable by the green and distinctly crackled cap cuticle; Russula xerampelina – an edible russula that smells and tastes like shrimp or seafood.
=== Type III === A civilization with energy on the scale of its own galaxy, with an energy consumption of ≈4×1044 erg/s. Lemarchand defined civilizations of this type as having access to energy comparable to the luminosity of the entire Milky Way galaxy, about ≈4×1044 erg/s" (≈4×1037 watts). In accordance with the data available at the time, Kardashev did not go beyond a Type III civilization. However, new types (0, IV, V, and VI) have been proposed.
== Notable academic journal articles == "Intracellular reduction of selenite into glutathione peroxidase... " - US National Library of Medicine - 2000 "Vestibular Dysfunction in DFNB1 Deafness" - US National Library of Medicine - 2011
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.